Clinical trials: Tumour, Residual
Cervical Intraepithelial Neoplasia
Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol
The purpose of this study is to investigate if imiquimod can be used as a non-invasive option in the treatment of residual/recurrent CIN lesions.
- Trial name
- TopIC-2 (NCT02669459)
- Testing
- Imiquimod, LLETZ
- Where
- Netherlands
- Volunteers
- 433 people
- Sponsor
- Erasmus Medical Center
Biliary Tract Cancer
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence Surveillance
This is a prospective, observational, single-center study. The purpose of this study is to evaluate the efficacy of circulating tumor mitochondrial DNA (ct-mtDNA) in plasma as a biomarker for minimal residual disease (MRD)…
- Trial name
- CCGLC-016 (NCT06653127)
- Testing
- Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tongji Hospital
Ovarian Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with peripheral stem cell transplantation may allow the doctor to give higher…
- Trial name
- NCT00003413
- Testing
- filgrastim, carmustine, cisplatin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Maryland, Baltimore
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden
This phase II trial evaluates whether a multi-antigen vaccine called STEMVAC improves disease-free survival after surgery in patients with triple-negative breast cancer (TNBC) and moderate or extensive residual cancer burden.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Trial name
- NCT07721259
- Testing
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Biospecimen Collection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Ovarian Neoplasms, Carcinoma, Ovarian Epithelial
Blood-Based Minimal Residual Disease in Advanced Epithelial Ovarian Cancer After 1st Line Therapy
The purpose of this observational study is to learn if a specialized blood test can help predict whether advanced ovarian cancer will return after a patient's initial treatments are finished.
- Conditions
- Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, Ovarian Cancer
- Trial name
- NCT07670962
- Testing
- Blood-based ctDNA minimal residual disease (MRD) test
- Volunteers
- 300 people
- Sponsor
- Asan Medical Center
Relapsed/Refractory AML, Minimal Residual Disease Positive AML
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
The purpose of this First-in-Human Phase 1 study is to determine if AMG 330 given as a continuous IV infusion is safe and tolerable in adult subjects that have myeloid malignancies, and to determine the maximum tolerated dose…
- Conditions
- Relapsed/Refractory AML, Minimal Residual Disease Positive AML, Myelodysplastic Syndrome
- Trial name
- NCT02520427
- Testing
- AMG 330
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 95 people
- Sponsor
- Amgen
Multiple Myeloma
Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
This is a Phase 2 study, open-label, 2-cohort, multicenter, national, interventional in patients with newly diagnosed multiple myeloma.
- Trial name
- IFm2022-01 (NCT06353022)
- Testing
- Teclistamab, Talquetamab, Lenalidomide
- Where
- 19 sites in France
- Volunteers
- 103 people
- Sponsor
- Nantes University Hospital
Breast Cancer
Treatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast Cancer
Breast cancer seriously threatens the health of women worldwide. The HER-2-positive subtype accounts for approximately 15% to 20%, featuring strong invasiveness and poor prognosis.
- Trial name
- NCT07132502
- Testing
- ctDNA MRD
- Volunteers
- 24 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma Resectable
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
This study will conduct a prospective cohort study to verify the predictive value of ctDNA-MRD longitudinal monitoring model in predicting postoperative recurrence, verify whether ctDNA-MRD longitudinal monitoring model can…
- Trial name
- NCT06157060
- Testing
- circulating tumor DNA
- Where
- 7 sites in China
- Volunteers
- 255 people
- Sponsor
- Zhujiang Hospital
Acute Myeloid Leukemia, Adult
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
The MAURITIUS trial is a single-arm, multicenter phase II study of single treatment with midostaurin being applied to AML (acute myeloid leukemia) patients with activating FLT3 (FMS-like tyrosine kinase3) mutations and either…
- Trial name
- NCT03951961
- Testing
- Midostaurin
- Where
- 4 sites in Germany
- Volunteers
- 1 people
- Sponsor
- University of Jena
Neuroma, Phantom Limb Pain After Amputation
Ultrasound-Guided Platelet-Rich Plasma Versus Local Anesthetic Injection for Chronic Neuroma Pain After Combat-Related Amputation
Patients with combat-related amputations frequently experience chronic neuroma pain that may interfere with rehabilitation, prosthesis use, mobility, sleep, and quality of life.
- Conditions
- Neuroma, Phantom Limb Pain After Amputation, Stump Pain, Platelet-rich Plasma (PRP)
- Trial name
- PRP-NEUROMA (NCT07624890)
- Testing
- Platelet-Rich Plasma (PRP) Injections, Local Anesthetic Injection
- Where
- 2 sites in Ukraine
- Volunteers
- 100 people
- Sponsor
- Ukrainian Society of Regional Anesthesia and Pain Therapy
CLL
CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.
A recent study showed that 6 cycles of obinutuzumab when given after at least 1 year of ibrutinib did result in MRD conversion in a significant proportion of patients (50%).
- Trial name
- NCT04639362
- Testing
- ibrutinib, venetoclax, obinutuzumab, ibrutinib, venetoclax
- Where
- 27 sites in Denmark, Netherlands
- Volunteers
- 85 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland